Trials / Completed
CompletedNCT03027245
Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy
Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 353 (actual)
- Sponsor
- Eisai GmbH · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study E7389-M044-504 is an observational, post-authorization, single-arm, prospective, multicenter cohort study conducted to characterize and determine the incidence of eribulin-induced peripheral neuropathy (PN), and the frequency and time to resolution of eribulin-induced PN in adult participants treated with eribulin in a real-life setting with locally advanced or metastatic breast cancer (MBC) who have progressed following at least one and up to three chemotherapeutic regimens for advanced disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eribulin |
Timeline
- Start date
- 2016-10-13
- Primary completion
- 2022-05-31
- Completion
- 2022-05-31
- First posted
- 2017-01-23
- Last updated
- 2022-07-13
Locations
65 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT03027245. Inclusion in this directory is not an endorsement.